Antibody - based cancer therapy
A recent article published in Oncogene journal covers a detailed review on rapidly developing field of antibody-based cancer therapy. This treatment regimen have evolved into a successful clinical and commercial project. Interestingly, around 50% of all antibody therapeutics on the market are created for use in oncology. There are 3 main categories of antibody cancer treatment, that are based on mechanisms of action, properties, engagement and delivery of cytotoxic cells. According to the authors, there are 43 FDA-approved and marketed antibody-based cancer therapies providing a number of formats, targets, and indications. Moreover, there are new treatment developments based on mechanism of action, that are currently at various stages of preclinical and clinical investigations. That menas that it is expected to have even more FDA approvals in coming years. Next-generation antibody engineering is a successful vector for these pharmaceuticals. More by the link!